171 related articles for article (PubMed ID: 35169091)
1. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
Ichikawa T; Niida Y
No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
3. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.
Bongaarts A; van Scheppingen J; Korotkov A; Mijnsbergen C; Anink JJ; Jansen FE; Spliet WGM; den Dunnen WFA; Gruber VE; Scholl T; Samueli S; Hainfellner JA; Feucht M; Kotulska K; Jozwiak S; Grajkowska W; Buccoliero AM; Caporalini C; Giordano F; Genitori L; Coras R; Blümcke I; Krsek P; Zamecnik J; Meijer L; Scicluna BP; Schouten-van Meeteren AYN; Mühlebner A; Mills JD; Aronica E
Brain; 2020 Jan; 143(1):131-149. PubMed ID: 31834371
[TBL] [Abstract][Full Text] [Related]
4. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
5. TSC2 somatic mosaic mutation, including extra-tumor tissue, may be the developmental cause of solitary subependymal giant cell astrocytoma.
Sasaki T; Uda T; Kuki I; Kunihiro N; Okazaki S; Niida Y; Goto T
Childs Nerv Syst; 2022 Jan; 38(1):77-83. PubMed ID: 34741623
[TBL] [Abstract][Full Text] [Related]
6. Isolated subependymal giant cell astrocytoma (SEGA) in the absence of clinical tuberous sclerosis: two case reports and literature review.
Cobourn KD; Chesney KM; Mueller K; Fayed I; Tsering D; Keating RF
Childs Nerv Syst; 2024 Jan; 40(1):73-78. PubMed ID: 37658938
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
Ebrahimi-Fakhari D; Franz DN
Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
[TBL] [Abstract][Full Text] [Related]
8. Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex.
Kotulska K; Borkowska J; Mandera M; Roszkowski M; Jurkiewicz E; Grajkowska W; Bilska M; Jóźwiak S
Childs Nerv Syst; 2014 Dec; 30(12):2037-42. PubMed ID: 25227171
[TBL] [Abstract][Full Text] [Related]
9. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
[TBL] [Abstract][Full Text] [Related]
10. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile.
Giannikou K; Zhu Z; Kim J; Winden KD; Tyburczy ME; Marron D; Parker JS; Hebert Z; Bongaarts A; Taing L; Long HW; Pisano WV; Alexandrescu S; Godlewski B; Nellist M; Kotulska K; Jozwiak S; Roszkowski M; Mandera M; Thiele EA; Lidov H; Getz G; Devinsky O; Lawrence MS; Ligon KL; Ellison DW; Sahin M; Aronica E; Meredith DM; Kwiatkowski DJ
Mod Pathol; 2021 Feb; 34(2):264-279. PubMed ID: 33051600
[TBL] [Abstract][Full Text] [Related]
11. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
[TBL] [Abstract][Full Text] [Related]
12. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
13. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients.
Kotulska K; Borkowska J; Roszkowski M; Mandera M; Daszkiewicz P; Drabik K; Jurkiewicz E; Larysz-Brysz M; Nowak K; Grajkowska W; Domańska-Pakieła D; Jóźwiak S
Pediatr Neurol; 2014 Apr; 50(4):307-12. PubMed ID: 24507694
[TBL] [Abstract][Full Text] [Related]
14. Everolimus tablets for patients with subependymal giant cell astrocytoma.
Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
[TBL] [Abstract][Full Text] [Related]
15. Subependymal giant-cell astrocytomas in the absence of tuberous sclerosis.
Reynolds RA; Aum DJ; Gonzalez-Gomez I; Wong M; Roberts K; Dahiya S; Rodriguez LF; Roland JL; Smyth MD
J Neurosurg Pediatr; 2023 Sep; 32(3):351-357. PubMed ID: 37327147
[TBL] [Abstract][Full Text] [Related]
16. Identification of TSC1 or TSC2 mutation limited to the tumor in three cases of solitary subependymal giant cell astrocytoma using next-generation sequencing technology.
Fohlen M; Harzallah I; Polivka M; Giuliano F; Pons L; Streichenberger N; Dorfmüller G; Touraine R
Childs Nerv Syst; 2020 May; 36(5):961-965. PubMed ID: 32103336
[TBL] [Abstract][Full Text] [Related]
17. The Characterization of a Subependymal Giant Astrocytoma-Like Cell Line from Murine Astrocyte with mTORC1 Hyperactivation.
Tang X; Angst G; Haas M; Yang F; Wang C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923449
[TBL] [Abstract][Full Text] [Related]
18. Subependymal giant cell astrocytoma in a genetically negative tuberous sclerosis complex adult: Case report.
Konakondla S; Jayarao M; Skrade J; Giannini C; Workman MJ; Morgan CJ
Clin Neurol Neurosurg; 2016 Nov; 150():177-180. PubMed ID: 27690251
[TBL] [Abstract][Full Text] [Related]
19. Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations.
Jóźwiak S; Nabbout R; Curatolo P;
Eur J Paediatr Neurol; 2013 Jul; 17(4):348-52. PubMed ID: 23391693
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
